EXT418, a novel long-acting ghrelin, mitigates Lewis lung carcinoma induced cachexia in mice.

ABSTRACT:

Background

Ghrelin is a potential therapy for cachexia due to its orexigenic properties and anabolic effects on muscle and fat. However, its clinical use is limited by the short half-life of active (acylated) ghrelin (~11 min in humans). EXT418 is a novel long-acting, constitutively active ghrelin analog created by covalently linking it to a vitamin D derivative. Here, we evaluated the effects and mechanisms of action of EXT418 on Lewis lung carcinoma (LLC)-induced cachexia in mice.

Methods

Male C57BL/6J mice (5- to 7-month-old) were implanted with 1 × 10⁶ heat-killed (HK) or live LLC cells. When the tumour was palpable, mice were injected with vehicle (T + V) or EXT418 daily (T + 418 Daily, 0.25 mg/kg/day) or every other day (T + 418 EOD, 0.5 mg/kg/EOD) for up to

SUBMITTER: Kerr HL 

PROVIDER: S-EPMC10235874 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature